These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

722 related items for PubMed ID: 24678812

  • 1. The CXCL8/IL-8 chemokine family and its receptors in inflammatory diseases.
    Russo RC, Garcia CC, Teixeira MM, Amaral FA.
    Expert Rev Clin Immunol; 2014 May; 10(5):593-619. PubMed ID: 24678812
    [Abstract] [Full Text] [Related]

  • 2. Combined anti CXC receptors 1 and 2 therapy is a promising anti-inflammatory treatment for respiratory diseases by reducing neutrophil migration and activation.
    Planagumà A, Domènech T, Pont M, Calama E, García-González V, López R, Aulí M, López M, Fonquerna S, Ramos I, de Alba J, Nueda A, Prats N, Segarra V, Miralpeix M, Lehner MD.
    Pulm Pharmacol Ther; 2015 Oct; 34():37-45. PubMed ID: 26271598
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W, Fan X, Hesk D, Fossetta J, Qiu H, Jakway J, Billah M, Dwyer M, Chao J, Deno G, Taveras A, Lundell DJ, Hipkin RW.
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [Abstract] [Full Text] [Related]

  • 4. Rabbit neutrophil chemotactic protein (NCP) activates both CXCR1 and CXCR2 and is the functional homologue for human CXCL6.
    Catusse J, Struyf S, Wuyts A, Weyler M, Loos T, Gijsbers K, Gouwy M, Proost P, Van Damme J.
    Biochem Pharmacol; 2004 Nov 15; 68(10):1947-55. PubMed ID: 15476666
    [Abstract] [Full Text] [Related]

  • 5. CXCL8((3-73))K11R/G31P antagonizes ligand binding to the neutrophil CXCR1 and CXCR2 receptors and cellular responses to CXCL8/IL-8.
    Li F, Zhang X, Gordon JR.
    Biochem Biophys Res Commun; 2002 May 10; 293(3):939-44. PubMed ID: 12051749
    [Abstract] [Full Text] [Related]

  • 6. LPS challenge in healthy subjects: an investigation of neutrophil chemotaxis mechanisms involving CXCR1 and CXCR2.
    Aul R, Patel S, Summerhill S, Kilty I, Plumb J, Singh D.
    Int Immunopharmacol; 2012 Jul 10; 13(3):225-31. PubMed ID: 22561413
    [Abstract] [Full Text] [Related]

  • 7. The combined CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks neutrophil infiltration, pyrexia, and pulmonary vascular pathology in endotoxemic animals.
    Gordon JR, Li F, Zhang X, Wang W, Zhao X, Nayyar A.
    J Leukoc Biol; 2005 Dec 10; 78(6):1265-72. PubMed ID: 16204619
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The activation of IL-8 receptors in cultured guinea pig Müller glial cells is modified by signals from retinal pigment epithelium.
    Malgorzata Goczalik I, Raap M, Weick M, Milenkovic I, Heidmann J, Enzmann V, Wiedemann P, Reichenbach A, Francke M.
    J Neuroimmunol; 2005 Apr 10; 161(1-2):49-60. PubMed ID: 15748943
    [Abstract] [Full Text] [Related]

  • 10. The Clinicopathological Significance of the CXCR2 Ligands, CXCL1, CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8 in Gastric Cancer.
    Yamamoto Y, Kuroda K, Sera T, Sugimoto A, Kushiyama S, Nishimura S, Togano S, Okuno T, Yoshii M, Tamura T, Toyokawa T, Tanaka H, Muguruma K, Ohira M, Yashiro M.
    Anticancer Res; 2019 Dec 10; 39(12):6645-6652. PubMed ID: 31810929
    [Abstract] [Full Text] [Related]

  • 11. ELR-CXC chemokine receptor antagonism targets inflammatory responses at multiple levels.
    Zhao X, Town JR, Li F, Zhang X, Cockcroft DW, Gordon JR.
    J Immunol; 2009 Mar 01; 182(5):3213-22. PubMed ID: 19234219
    [Abstract] [Full Text] [Related]

  • 12. Treatment with DF 2162, a non-competitive allosteric inhibitor of CXCR1/2, diminishes neutrophil influx and inflammatory hypernociception in mice.
    Cunha TM, Barsante MM, Guerrero AT, Verri WA, Ferreira SH, Coelho FM, Bertini R, Di Giacinto C, Allegretti M, Cunha FQ, Teixeira MM.
    Br J Pharmacol; 2008 May 01; 154(2):460-70. PubMed ID: 18362895
    [Abstract] [Full Text] [Related]

  • 13. Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist.
    Nicholls DJ, Wiley K, Dainty I, MacIntosh F, Phillips C, Gaw A, Mårdh CK.
    J Pharmacol Exp Ther; 2015 May 01; 353(2):340-50. PubMed ID: 25736418
    [Abstract] [Full Text] [Related]

  • 14. Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer.
    Nasser MW, Raghuwanshi SK, Grant DJ, Jala VR, Rajarathnam K, Richardson RM.
    J Immunol; 2009 Sep 01; 183(5):3425-32. PubMed ID: 19667085
    [Abstract] [Full Text] [Related]

  • 15. Heparin-bound chemokine CXCL8 monomer and dimer are impaired for CXCR1 and CXCR2 activation: implications for gradients and neutrophil trafficking.
    Joseph PRB, Sawant KV, Rajarathnam K.
    Open Biol; 2017 Nov 01; 7(11):. PubMed ID: 29118271
    [Abstract] [Full Text] [Related]

  • 16. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A, Bertini R, Mosca M, Bizzarri C, Anacardio R, Triulzi S, Allegretti M, Ghezzi P, Villa P.
    Eur Cytokine Netw; 2006 Mar 01; 17(1):35-41. PubMed ID: 16613761
    [Abstract] [Full Text] [Related]

  • 17. Differential Effects of Posttranslational Modifications of CXCL8/Interleukin-8 on CXCR1 and CXCR2 Internalization and Signaling Properties.
    Vacchini A, Mortier A, Proost P, Locati M, Metzemaekers M, Borroni EM.
    Int J Mol Sci; 2018 Nov 27; 19(12):. PubMed ID: 30486423
    [Abstract] [Full Text] [Related]

  • 18. Neutrophil chemotaxis caused by chronic obstructive pulmonary disease alveolar macrophages: the role of CXCL8 and the receptors CXCR1/CXCR2.
    Kaur M, Singh D.
    J Pharmacol Exp Ther; 2013 Oct 27; 347(1):173-80. PubMed ID: 23912333
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2.
    Casilli F, Bianchini A, Gloaguen I, Biordi L, Alesse E, Festuccia C, Cavalieri B, Strippoli R, Cervellera MN, Di Bitondo R, Ferretti E, Mainiero F, Bizzarri C, Colotta F, Bertini R.
    Biochem Pharmacol; 2005 Feb 01; 69(3):385-94. PubMed ID: 15652230
    [Abstract] [Full Text] [Related]

  • 20. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
    Bizzarri C, Beccari AR, Bertini R, Cavicchia MR, Giorgini S, Allegretti M.
    Pharmacol Ther; 2006 Oct 01; 112(1):139-49. PubMed ID: 16720046
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.